Aspirin News and Research RSS Feed - Aspirin News and Research

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
Aspirin may help boost effectiveness of cancer treatment

Aspirin may help boost effectiveness of cancer treatment

Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday). [More]
Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications increases in IHD but levels still suboptimal

Treatment with life-saving medications has increased over the past ten years in ischaemic heart disease but levels are still suboptimal, according to the first results of the Chronic Ischaemic Cardiovascular Disease (CICD) Pilot Registry presented today at ESC Congress 2015 and published in European Heart Journal. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada. [More]
DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year. [More]
Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today. [More]
ESC publishes new guidelines on pericardial diseases

ESC publishes new guidelines on pericardial diseases

New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life. [More]
Obesity raises Lynch syndrome CRC risk

Obesity raises Lynch syndrome CRC risk

Obesity increases the risk of colorectal cancer in patients with Lynch syndrome, research indicates, but daily aspirin use may combat this excess risk. [More]
Childhood cancer survivors have high risk of suffering stroke at young age

Childhood cancer survivors have high risk of suffering stroke at young age

Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood cancer have a high risk of suffering a stroke at a surprisingly young age. [More]
Physical inactivity poses important clinical, public health and fiscal challenges for the U.S.

Physical inactivity poses important clinical, public health and fiscal challenges for the U.S.

What do a prominent physiologist and two-time survivor of pancreatic cancer and a world-renowned researcher whose landmark discoveries on aspirin, drug therapies of proven benefit and therapeutic lifestyle changes that have saved more than 1.1 million lives have in common? They are both passionate about the importance of regular physical activity in reducing risks of dying from heart attacks and strokes, as well as developing diabetes, hypertension and colon cancer. And more importantly, enhancing mental health and fostering healthy muscles, bones and joints in all Americans from childhood to the elderly. [More]
Study reveals how inflammation triggers colon cancer cells to metastasize

Study reveals how inflammation triggers colon cancer cells to metastasize

A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois, M.D., Ph.D., has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize. [More]
Loyola University Medical Center first in Illinois to offer new, noninvasive test for heart disease

Loyola University Medical Center first in Illinois to offer new, noninvasive test for heart disease

Loyola University Medical Center is the first and only hospital in Illinois to offer a new, noninvasive technology to test for coronary artery disease. [More]
FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults. [More]
New scientific conference 'Aspirin in the 21st Century' to be held in London

New scientific conference 'Aspirin in the 21st Century' to be held in London

What more can be said about aspirin, a medicine that was first prescribed at the end of the 19th century? It is known and accepted in every country. For over a hundred years it has been the standard by which all other, newer, painkillers have had to be judged, and it has never been found to be inferior. It is still considered the world's leading analgesic. [More]
Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications. [More]
New review points to most promising areas for liposomes' further development

New review points to most promising areas for liposomes' further development

An international group of scientists, including Vladimir Chupin, head of the Biophysics Section at MIPT, and Vladimir Torchilin (Northeastern University, the USA), one of the world's leading experts in pharmacology, recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs. [More]
FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. [More]
New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

A Veterans Affairs database study of more than 83,000 patients found that men whose low testosterone was restored to normal through gels, patches, or injections had a lower risk of heart attack, stroke, or death from any cause, versus similar men who were not treated. [More]
Researchers establish safety, dosing of new drug for treating blood cancers

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology. [More]
University Hospital recognized for providing high standard of care for heart attack patients

University Hospital recognized for providing high standard of care for heart attack patients

University of Missouri Health Care's University Hospital has received the American College of Cardiology's ACTION Registry-Get with the Guidelines (GWTG) Silver Performance Achievement Award for 2015. [More]
Advertisement
Advertisement